Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Evidence from the post-marketing safety data analysis identified a strong association between incretin mimetics and pancreatic events. Fewer events in RCTs may justify insignificant meta-analysis results.PMID:37986140 | DOI:10.1080/14740338.2023.2284992
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Asif Muhammad Christy Thomas Vivekanandan Kalaiselvan Krishna Undela Source Type: research
More News: Cancer & Oncology | Carcinoma | Diabetes | Drugs & Pharmacology | Empagliflozin | Endocrinology | Incretin Therapy | Januvia | Jardiance | Pancreas | Pancreatic Cancer | Pancreatitis | Study